Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a spectrum of very different manifestations and ...

At the time when patients with lupus, or systemic lupus erythematosus (SLE), are diagnosed, approximately 15% to 30% will ...

Clinical Trials of Budoprutug in Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE) Underway; Trial of Budoprutug in Primary Membranous Nephropathy (pMN) Expected to Initiate in the ...

Novartis announces positive results from VAYHIT2 phase III trial of ianalumab plus eltrombopag in patients with primary immune thrombocytopenia: Basel Wednesday, August 13, 2025, ...

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected ...

Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - ...

Researchers are developing a new approach to preventing lupus nephritis – improving the health and function of the cells that ...

In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

The Lupus Foundation of America, the national force devoted to solving the cruel mystery of lupus, announced the appointment ...

India: A recent study from India has revealed that kidney involvement is highly prevalent among children diagnosed with ...